Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03117140 · ClinicalTrials.gov registry record · Phase 4

Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block

A Phase 4 study, sponsored by Melinda Seering.

Completed
Registry status
Phase 4
Development phase
160
Enrollment target

NCT03117140 is a Phase 4 study that has completed, run by Melinda Seering. The registered enrollment target is 160 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03117140, a Phase 4 study, has completed, sponsored by Melinda Seering.

COMPLETED
Registry status
Phase 4
Development phase
160 participants
Enrollment target

Study Summary

This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain ropivacaine alone.

Interventions

  • DRUG Ropivacaine 0.75%
  • DRUG Ropivacaine 0.75% + 300 mcg Buprenorphine
  • DRUG Ropivacaine 0.75% + 75 mcg clonidine
  • DRUG Ropivacaine 0.75% + 8 mg dexamethasone

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2013-12
Est. Completion 2017-03
Phase Phase 4

Sponsor

Melinda Seering

3 total trials

What the Registry Record Tells You About NCT03117140

The ClinicalTrials.gov registry entry for NCT03117140 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinda Seering, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Ropivacaine 0.75% is the first listed.

NCT03117140 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03117140 about?

NCT03117140 is a clinical study titled "Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block". This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain ropivacaine alone.

What is the current status of trial NCT03117140?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2013-12. Estimated completion is 2017-03.

What interventions are being tested in trial NCT03117140?

The interventions under investigation include: Ropivacaine 0.75% (DRUG), Ropivacaine 0.75% + 300 mcg Buprenorphine (DRUG), Ropivacaine 0.75% + 75 mcg clonidine (DRUG), Ropivacaine 0.75% + 8 mg dexamethasone (DRUG).

Who is sponsoring clinical trial NCT03117140?

This trial is sponsored by Melinda Seering, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.